International Journal of Radiation Oncology, Biology, Physics 1994: Vol 29 Index

8 Pages·1994·2.9 MB·English

AUTHOR INDEX
Volume 29, 1994
Abe, M., 239, 579, 583, 587, 591, Bonner, J. A., 243 Cole, S., 339 Fisher, J., 559
595, 1089 Bosset, J.-F., 205 Coleman, C. N., 249, 289, 357, 379, Fitzpatrick, P. J., 195
Abra, R. M., 827 Bottcher, H. D., 183, 220 407, 535, 541, 545, 611, 617 Fitzsimmons, S. A., 427
Abramson, D. H., 729 Botteron, P., 1167 Collier, J. M., 647 Flomenberg, N., 847
Adamietz, I. A., 183, 220 Boulad, F., 847 Constantinescu, A., 95 Folven, B. R., 243
Adams, G. E., 231, 285, 329, 333, Bouzy, J., 953 Cook, J. A., 559 Fontanesi, J., 1199
339, 369, 443, 463 Bowen, M. G., 529 Cooper, J. S., 661 Fornasier, V., 1005
Adcock, L. L., 989 Boyce, D. J., 459 Corn, B., 969 Fowler, J. F., 105, 209, 989, 1079,
Agrawal, K. C., 397 Bradley, J. K., 329, 463 Coughlin, C. T., 1065 1195
Akaboshi, M., 81, 239 Brady, L. W., 1049 Counsell, C. J. R., 285 Fraas, B. A., 1125
Akagi, K., 505 Brambs, H.-J., 855 Cox, J. A., 1119 Frazier, L. C., 841
Akanuma, A., 631 Brand, R., 711 Cox, J. D., 1183 Freeman, D. E., 169, 983
Akashi, M., 631 Braunhut, S. J., 249 Cruikshank, G., 427 Freund, U., 855
Akuta, K., 81, 239 Bremner, J. C. M., 285, 329, 463 Cummings, B. J., 195, 1005 Fries, P. D., 177
Alastuey, I., 1201 Brenner, D. J., 893 Cygler, J., 1157 Fritz, P., 855
Alecci, M., 421 Britsch, A., 687 Fu, K. K., 661
Aletti, P., 673, 681 Brochstein, J., 847 Daftari, I., 647 Fuchihata, H., 705
Alexander, III, E., 617 Brown, A. E., 163 Dartois, D., 681 Fuks, Z., 755, 847, 863
Anderson, W. J., 781 Brown, I., 115 Dass, K. K., 187 Furukawa, S., 705
Ando, K., 239, 621 Brown, J. M., 493 Davis, M. A., 519
Ang, K. K., 67 Broxmeyer, H. E., 821 Deeg, H. J., 39 Gabel, M., 555
Antich, P. P., 95 Bump, E. A., 249, 407, 289 Deen, D. F., 1041 Gadner, H., 39
Aoki, Y., 631 Burman, C. M., 755 DeLaney, T. F., 735 Gallion, H. H., 529
Aoyama, T., 627 Busse, P. M., 535 Delfs, J. R., 289 Gaspar, L. E., 835
Au, G. K. H., 699 Buswell, L., 535, 541, 545, 611 DeLuca, A. M., 781, 1015 Gauger, G., 647
Butler, E. B., 213 Denison, L., 549 Geard, C. R., 267, 565
Babcock, E. E., 95 Byhardt, R. W., 661 Denny, W. A., 311, 317, 323 Geisinger, K. R., 841
Bacher, J. D., 1015 DePriest, P., 529 George, W. J., 397
Baeker, J. R., 1085 Cahill, R., 39 Ding, L., 393 Gerard, J.-P., 17, 215
Baguley, B. C., 373 Cairncross, J. G., 835 Doggett, R. L. S., 661, 961 Gerbaulet, A., 953
Bahary, J.-P., 647 Capellari, J. O., 841 Doherty, N., 379 Gerritsen, M., 295
Baille-Johnson, H., 3 Caplan, R. J., 1183 Donaldson, S. S., 883 Gerweck, L. E., 57
Bamberg, M., 869 Carlson, J. W., 989 Dorie, M. J., 805 Giaccia, A. J., 259
Bardelli, D., 45 Carmichael, J., 277, 369 Down, J. D., 218 Gillio, A., 847
Barnes, M., 781 Carson, L. F., 989, 1079 Durand, R. E., 481, 487 Glasgow, G. P., 1175
Bartelink, H., 205 Castro, J. R., 647, 1027 Dusenbery, K. E., 989, 1079 Glazer, H. S., 1105
Bauman, G. S., 835 Castro-Malaspina, H., 847 Gogu, S. R., 397
Beard, C., 611 Catton, C. N., 1005 Edgren, M. R., 403 Goodman, H., 545
Belfi, C. A., 473 Cavaletti, G., 763 Edmonds, P. M., 3 Gospodarowicz, M. K., 195
Bentel, G. C., 879, 903 Cellai, E., 25 Edwards, D. I., 307 Goswitz, J. J., 989
Bentzen, S. M., 941 Cerce, B. A., 249 Efird, J. T., 657 Gould, R. C., 216
Berger, C., 17 Chadwick, J. A., 499 Eifel, P. J., 9 Graham, M. V., 1105
Bergeron, R. J., 1041 Chan, W., 813 Eisbruch, A., 217 Grant, W., 213
Berkowitz, R., 545 Chandini, R., 383 Elkind, M. M., 577 Grau, C., 439, 449
Bernier, J., 1189 Chaplin, D. J., 363, 439, 467, 499 Ellsworth, R. M., 729 Green, A., 549
Berns, C., 855 Chapman, J. D., 351 Emami, B., 1105 Green, M. R., 1085
Bertoni, F., 45 Chappell, R., 191 Engin, K., 125 Greven, K. M., 841
Bertrand, K., 1139 Chen, C.-Z., 1041 Ennis, R., 1133 Griffin, R. J., 433
Bey, P., 673, 681 Chen, E. Y., 259 Erickson, B. A., 1095 Griffin, T. W., 1187
Bhattathiri, V. N., 383 Cheng, A. C. K., 699 Eschwege, F., 149 Griffith, O. W., 407
Biaglow, J. E., 357 Childs, B., 847 Evans, G., 999 Grigsby, P. W., 217, 961
Bielajew, A. F., 1157 Choi, I.-B., 433 Grob, E., 1167
Bieri, S., 1167 Choy, D., 699 Fariss, A. K., 177 Gutin, P. H., 647, 719
Biti, G., 25 Christensen, K. L., 455 Feeley, M. M., 133
Blach, L. E., 735 Christianson, T. J. H., 243 Fein, D. A., 169 Ha-Kawa, S. K., 505
Black, P. McL., 617 Chung, C. T., 177, 1085 Fenton, B. M., 459 Haaxma-Reiche, H., 711
Black, P., 847 Ciottoli, G. B., 45 Ferrari, M., 421 Habara, Y., 511
Boddi, V., 25 Clark, J., 535 Fielden, E. M., 333, 339 Hahn, E. W., 95
Boles, M., 1085 Clery, M., 661, 961 Fietkau, R., 1049 Hahn, G. M., 827
Bollinger, B. K., 781 Cliffe, S., 323 Fisher, B. J., 835 Haie-Meder, C., 953
XVI
Hall, E. J., 267, 273, 891, 893 Jin, Y., 393 Levendag, P. C., 873 Minoia, C., 771
Hallahan, D. E., 777 Johnson, D., 611 Lewis, A. D., 427 Miralbell, R., 1167
Halperin, E. C., 835 Johnstone, P. A. S., 735, 781, 1015 Liebman, J., 559 Mitchell, J. B., 357, 559
Hamers, H. P., 205 Jones, J. M., 565 Liermann, D., 183 Mitchell, J. S., 115
Hammond, E., 661 Joseph, P., 351 Lindeboom, J., 1201 Mithal, N. P., 1011
Hampshire, V. A., 1015 Linstadt, D. E., 647 Mitsuhashi, N., 975
Hancock, S. L., 379 Kagan, A. R., 197 Loeffler, J. S., 617 Montagut, J., 1201
Hanson, W. R., 273 Kaklamanis, L., 277 Lonergan, S. J., 499 Montero, M., 1167
Hao, Y., 1005 Kalish, L. A., 541, 545 Lu, L., 821 Morgan, L. S., 169, 983
Happersett, L., 755 Kallman, R. F., 805 Luboinski, B., 149 Mori, T., 601
Haraf, D. J., 153, 216 Kalra, R., 285 Luporsi, E., 673, 681 Morris, M., 9
Harari, P. M., 209 Kanno, T., 511 Lusinchi, A., 149 Moselen, J. W., 323
Harkness, B. A., 841 Kano, E., 511 Lynch, E. M., 439 Moss, W. T., 687
Harms, Sr., W. B., 1105 Karim, A. B. M. F., 33, 1201 Mott, T., 3
Harris, A. L., 277, 369 Kawase, Y., 631 Macdonald, D. R., 835 Muehlenkamp, J. K., 1157
Harris, G. J., 1095 Kaye, S., 379 Mack, T., 1147 Murakami, S., 705
Harrison, A., 755 Kelly, D. P., 549 Mackie, T. R., 1157 Murata, R., 583, 587, 595
Harrison, L., 863 Kernan, N., 847 Macleod, K., 827 Murayama, C., 601
Harter, K. W., 1139 Kessler, M. L., 1125 MacPhail, S., 87 Muto, M., 545
Hasegawa, T., 433, 505 Keyes, Jr., J. W., 841 Madewell, B. R., 1027 Myskowski, P. L., 163
Hayakawa, K., 975 Khalil, A. A., 439, 449 Magno, L., 45
Hazard, L., 357 Khil, M. S., 555 Magrini, S. M., 25 Nagasawa, H., 601
Healy, J. B., 925 Kikuchi, H., 1089 Mahe, M. A., 17 Nah, B. S., 433
Hebert, M. E., 903 Kim, C. Y., 259 Maihle, N. J., 243 Nair, M. K.., 383
Hei, T. K., 267 Kim, I. H., 493 Majno, S. B., 1167 Nakajima, T., 601
Heimans, J. J., 1201 Kim, J. H., 555 Makepeace, C. M., 433 Nakano, H., 525
Hermans, J., 711 Kim, S. H., 555 Malaker, K., 289, 407 Nakatani, K., 525
Herndon, J. E., 1085 Kimura, H., 627 Malec, M. K., 719 Nakatsugawa, S., 635
Hess, C. F., 869 King, G. A., 177 Malissard, L., 673, 681 Naylor, M. A., 329, 339, 333
Hilburger, C. L., 397 Kinsella, T. J., 105, 781, 1015, 1195 Maltby, K., 789 Needham, P. R., 1011
Hill, R. P., 373 Kitakabu, Y., 583 Maniion, G., 205 Ngo, F. Q. H., 473
Hill, S. A., 439, 499 Koch, C. J., 345, 357 Marcus, Jr., R. B., 169, 983 Ni, C., 393
Hirschfeld, F., 1147 Koike, S., 239, 621 Mariscal, C., 379 Niél, C. G. J. H., 873
Hoekstra, F. H., 711 Kollath, J., 183 Mark, L. P., 1095 Niibe, H., 975
Hoffstetter, S., 673, 681 Kondo, T., 511 Marks, L. B., 879, 903 Ning, S., 827
Hogan, W. M., 969 Koong, A. C., 259 Marquez, C., 379 Niroomand-Rad, A., 1139
Holmes, M. A., 1157 Koper, P. C. M., 873 Martin, E., 969 Nishimoto, S.-I., 579
Holt, P. J., 1079 Kortmann, R.-D., 869 Martin, R. F., 549 Nishimura, Y., 141
Hoopes, P. J., 1065 Kotwall, C., 1005 Marton, L. J., 1041 Njo, K. H., 33
Hope-Stone, H. F., 3 Kozin, S. V., 505 Martus, P., 1049 Nolan, J., 333
Hori, H., 601 Kozminski, P., 673, 681 Maruyama, Y., 529 Noll, L., 611
Horiot, J.-C., 205 Kramar, A., 953 Masaki, N., 705 Noordijk, E. M., 711
Hornback, N. B., 821 Kreth, F. W., 220 Mason, R. P., 95 Nordsmark, M., 449
Horowitz, M. E., 735 Kubo, K., 705 Massaro, B. M., 1095 Nose, M., 631
Horsman, M. R., 439, 449, 455, 499 Kufe, D. W., 777 Masunaga, S., 81, 239 Nouet, P., 1167
Hoskin, P. J., 1011 Kusumoto, T., 545 Matsuno, E., 591 Nozaki, M., 975
Houlbrook, S., 369 Kutcher, G. J., 755 Matthews, D., 781 Nyaruba, M. M., 627
Hricak, H., 201 Kwok, T. T., 255 Matthews, J. W., 1105
Hu, L. J., 1041 Kwong, D. L. W., 699 Mauch, P. M., 218 O’Neill, P., 333
Hua, B. Y., 607 Kwong, P. W. K., 699 Maybaum, J., 519 O’Reilly, R., 847
Huan, L. C., 607 McCormick, B., 163, 729 O’Sullivan, B., 1005
Huang, A. H., 827 Lai, L. L., 249, 407 McCunniff, A. J., 999 Oda, Y., 1089
Huang, Y., 893 Lambin, P., 953 McDonald, S., 661, 747 Ohnishi, T., 525
Hurwitz, S. J., 289, 407, 545 Lambooij, N., 711 McFarlane, J. D., 125 Olive, P. L., 487
Hussey, D. H., 1191 LaNasa, P., 273 McGuire, W. A., 1079 Oliver, R. T. D., 3, 215
Lancar, R., 953 McGuirt, W. F., 841 Ong, J. Y. H., 3
Ikebuchi, M., 627 Lanciano, R., 969 McMillan, T. J., 1035 Ono, K., 81, 239
Ikeda, H., 705 Langley, R. E., 249, 289 Mcshan, D. L., 1125 Onoyama, Y., 601
Inayama, S., 601 LaPorte, R. M., 989 McWilliams, D., 813 Ortlieb, M., 39
Inoue, T., 705 Larson, D. A., 719 Medeiros, D., 249 Osborn, J. L., 433
Iro, H., 1049 Lartigau, E., 149 Meisner, C., 869 Ostertag, Ch. B., 220
Ishigaki, T., 587 Laver, J., 847 Mendenhall, W. M., 169, 983 Ostrowski, M. J., 3
Isono, K., 621 Lawrence, T. S., 519 Menke, M., 1147 Oswald, M. J., 9
Iwai, H., 579, 591, 595 Lee, P. C., 1175 Metsaars, J. A. L., 711 Overgaard, J., 439, 449, 455, 941
Lee, W. R., 983 Meyerowitz, C., 747 Oya, N., 579, 583, 587, 595
Jackson, A. W., 3 Leeper, D. B., 125 Mick, R., 153, 216
Jacobson, J., 735 Leibel, S. A., 755 Miller, R. C., 273 Padberg, G. W., 711
Jaiswal, A. K., 351 Leigh, B. R., 221 Million, R. R., 169, 983 Paggiarino, D. A., 999
Jany, R., 869 LePard, N. E., 481 Milroy, R., 295 Pajak, T. F., 661, 1183
XVII
Palayoor, S. T., 249, 289 Rosignoli, M. T., 45 Spanos, Jr., W. J., 961 Van Zijl, P., 317
Papanikolaou, N., 1157 Rouzaud, M., 1167 Spencer, D. P., 903 Vane, J. R., 443
Papi, M. G., 25 Roy, J., 863 Spitzer, T. R., 39 Vecht, C. J., 711
Pardee, M., 549 Rubin, P., 1, 645, 747, 789, 933 Sprague, M., 1015 Venzon, D. J., 735
Parkins, C. S., 499 Ruifrok, A. C. C., 73 Sreelekha, T. T., 383 Vijayakumar, T., 383
Pastyr, O., 1147 Rutland, M., 373 Steckel, R. J., 197 Vikse, C. M., 487
Patterson, A. V., 369 Ryan, T. P., 1065 Steinfeld, A. D., 961 Vinczan, A., 363
Paul, C. R., 473 Ryley, N., 277 Stephens, L. C., 67, 73 Virudachalam, S., 777
Pavy, J.-J., 205 Ryu, J., 1027 Stephens, M. A., 369 Visser, A. G., 873
Pedersen, D., 941 Ryu, S., 555 Stevens, Jr., K. R., 687 Vokes, E. E., 153, 216
Peiffert, D., 673, 681 Stobbe, C. C., 351 Voormolen, J. H. C., 711
Pelissier, E. P., 205 Sachs, R. K., 893 Storb, R., 218
Penney, D. P., 789 Sagerman, R. H., 177 Stratford, I. J., 231, 277, 285, 329, Wagner, J.-P., 17
Percarpio, B., 1133 Sakurai, H., 975 333, 339, 369, 443, 463 Wainson, A. A., 403
Perez, C. A., 217, 961 Sampson, L. E., 467 Streffer, C., 571 Wallner, K., 863
Pernot, M., 673, 681 Sanders, M., 213 Strohbehn, J. W., 1065 Wan, K. Y., 699
Peschel, R. E., 1133 Sansom, J. M., 285, 329, 443, 463 Sturm, V., 1147 Wang, C. C., 657
Peschke, P., 95 Saroff, D. M., 289 Sugahara, T., 229, 419, 627, 635 Wang, W., 393
Petereit, D. G., 1195 Sasai, K., 579, 583, 587, 591 Sugamoto, K., 627 Wannenmacher, M., 855
Peters, C., 39 Sauer, R., 1049 Sugiyama, T., 595 Wara, W. M., 719
Peters, L. J., 67, 1189 Sawada, H., 525 Suh, J. H., 187 Ware, D. C., 323
Petti, P. L., 647 Sawicka, J. M., 1175 Sutcliffe, S. B., 195 Warnke, P. C., 220
Philip, P. A., 277 Scalliet, P., 953 Sutherland, R. M., 255 Wasserman, T. H., 229, 419
Phillips, T. L., 201, 647, 719 Scarantino, C. W., 999 Sutton, B. M., 333, 339, 463 Watanabe, A., 525
Piao, C. Q., 267 Scharfen, C. O., 719 Suzuki, G., 631 Watson, Jr., N. E., 841
Plumb, J. A., 295 Schell, M. C., 187 Szabo, C., 443 Wattendorff, A. R., 711
Podgorsak, M. B., 1157 Scheremet, R., 220 Weaver, K. A., 719
Ponticelli, P., 25 Schieppati, M., 771 Tada, T., 601 Weichselbaum, R. R., 153, 216, 777
Porter, A. T., 1199 Schlegel, W., 1147 Takahashi, M., 579, 583, 975, 1089 Wells, C. M. M., 1157
Potish, R. A., 989, 1079 Schmidt, D. G., 1157 Takahashi, T., 975 Wen, P., 617
Poulter, C. A., 961 Schmidt-Ullrich, R. K., 813 Tamulevicius, P., 571 Wexler, L. H., 735
Powell, S. N., 1035 Schopohl, B., 183 Tanaka, Y., 505 Wharton, J. T., 9
Prados, M. D., 719 Schraube, P., 855 Tans, J. Th. J., 711 White, L. E., 397
Pratt, W. R., 3 Schultheiss, T. E., 67, 969 Taphoorn, M. J. B., 1201 Wierzbicki, J., 529
Precoma, J. C., 1167 Scott, C. S., 220 Taylor, M. L., 373 Wilkinson, J. M., 217
Price, R. E., 67 Seagren, S. L., 1085 Teague, D., 559 Williams, III, D. W., 841
Prosnitz, L. R., 903 Sebastian, P., 383 Tefft, M. C., 39, 187 Williams, M. V., 3
Pullen, S. M., 317 Seegenschmiedt, M. H., 1049 Teicher, B., 545 Williamson, J. F., 217
Purdy, J. A., 1105 Senan, S., 379 Ten Haken, R. K., 1125 Wilson, J. F., 935
Sham, J., 699 Tepper, J. E., 781 Wilson, L. D., 1133
Quaresima, V., 421 Shan, S., 473 Tercel, M., 317 Wilson, W. R., 311, 317, 323, 373
Shank, B., 847 Terraneo, F., 45 Wiltshire, C. R., 3
Raaphorst, G. P., 133 Shen, R.-N., 821 Termill, R. E., 781, 1015 Wolf, R., 277
Raben, M., 841, 1119 Sherouse, G. W., 903 Théon, A. P., 1027 Wong, W. W., 153, 216
Rampling, R., 379, 427 Shibamoto, Y., 579, 583, 587, 591, Thiemermann, C., 443 Woo, S. Y., 213
Ravikumar, T., 535 595, 1089 Thistlethwaite, A. J., 125 Wood, P. J., 285, 443, 463
Recht, A., 535 Shibata, T., 579, 583, 587, 595 Thobejane, S., 1139 Workman, P., 295, 427
Reckwerdt, P. J., 1157 Shidnia, H., 821 Thomas, A., 307
Reeves, N. J., 339, 463 Shimizutani, K., 705 Thomson, P., 295 Yaes, R. J., 924
Remani, P., 383 Shimm, D. S., 221 Tocher, J. H., 307 Yamada, S., 621
Rescigno, J., 163 Shulman, L. N., 379, 541, 545 Tordiglione, M., 45 Yamada, Y., 525
Reum, M., 549 Siemann, D. W., 229, 301, 387, Torrisi, J., 39 Yamakawa, M., 975
Révész, L., 403 419, 439, 789 Trask, C. W. L., 3 Yamashita, J., 1089
Richardson, M. E., 387 Siim, B. G., 311 Tredici, G., 771 Yang, J. C., 735
Rider, B. J., 397 Simpson, J. R., 220 Trembly, B. S., 1065 Yano, T., 525
Riese, N. E., 407, 617 Sindelar, W. F., 781, 1015 Trillet-Lenoir, V., 17 Yau, C. C., 699
Ritter, M. A., 105 Sipkema, D., 873 Tupchong, L., 125 Yi, X., 393
Roback, D. M., 989 Skarsgard, L. D., 363 Tuttle, S. W., 357 Yoshizawa, T., 579
Roberts, D. W., 1065 Skov, K. A., 87, 345 Twiggs, L. B., 1079 Young, C. W., 999
Roberts, M., 549 Skwarchuk, M. W., 369 Young, J., 847
Robertson, N., 369 Slotman, B. J., 33 Under, J. A., 989 Young, P., 821
Rocher, F. P., 17 Smudzin, T., 747 Urano, M., 141 Yuo, H. S., 177
Rodriguez, R., 105 Sneed, P. K., 719 Urban, C., 39
Roemeling, R. V., 379 Snoek, F. J., 1201 Ursini, C. L., 421 Zaghloul, M. S., 805
Rogers, D. W. O., 1157 Sohn, J. W., 187 Utsumi, H., 577 Zagoria, R. J., 1119
Romestaing, P., 17 Sombeck, M. D., 169, 983 Zaidi, S. T., 57
Rose, M., 549 Song, C. W., 433 Valerie, K. C., 813 Zelefsky, M. J., 755
Rose, M. A., 611 Sotgiu, A., 421 van der Kogel, A. J., 73 Zelefsky, M., 863
Rosenblum, N., 969 Spain, K., 243 Van Nagell, J. R., 529 Zietman, A., 57
XVIII
SUBJECT INDEX
Volume 29, 1994
A Carbogen, 81 Polymerase, 133
Carbon monoxide breathing, 449 Repair, 1035
Accelerated Carboplatin, 3, 545 Strand breaks, 487
Fractionation, 149, 617 Carboxyhemoglobin, 449 Dose
Radiotherapy, 711 Carcinoma, 863 Evaluation, 1125
Accuracy, 1175 Uterine cervix, 941 To air cavity tissue—air interface, 1139
Acute toxicity, 595 Cardiac toxicity, 903 To larynx, 1139
Adjuvant, 3 Carotid cannulation, 455 Dose-volume histogram, 1125
Adrenochrome monoaminoguanidine meth- CCNU, 301 Doxorubicin, 827
anesulfonate, 635 CDDP, 525 Drug
Age, 73 CDF1 mice, 455 Release, 827
AK-2123, 607 Cell Resistance, 387
Alkaline phosphatase, 115 Cycle, 267 DT-diaphorase, 231, 295, 351, 369, 427
Alternating chemo-radiotherapy, 1085 Kinetics, 105 dUTPase, 519
Anal canal carcinoma, 17 Membrane, 383 Dynamic MRI, 473
Anemia, 1079 Survival, 273
Animal models, 1015 Cellulitis, 163
E
Aorta, 781 Central nervous system, 67
Aplastic anemia, 847 Cepharanthin, 525
Early and late morbidity, 941
Apoptosis, 249, 289 Cerebrospinal fluid cytology, 1089
EBI, 673
Astatine-211, 115 Cervical
Effect of microenvironment, 363
Asymmetric collimator, 187 Cancer, 9, 873, 975
Elderly, 835
Azo/azoxy derivatives, 307 Carcinoma, 953
Electron
Cervix cancer, 969, 1079
Beam dosimetry, 1157
B2C¥ $29
B CFU-GM, 631 Paramagnetic resonance, 421
EMT6 spheroids, 323
Charged particle radiotherapy, 647
Endothelial cells, 249
BE-4-4-4, 1041 Chemo-neutron radiotherapy, 529
Endovascular irradiation, 183
Benzyl quarternary mustard, 317 Chemosensitization, 301
Enzyme profiling, 427
Bile duct(s), 781, 855 Chemotherapy, 17, 25, 705, 1089
EO9, 295
Bioreduction, 307 Chloramphenicol, 307
Epidermal growth factor, 243
Bioreductive Chronic hypoxia, 255
Receptor, 813
Agents, 295 Cisplatin, 771, 1027
Epithelial cancer of the eye, 177
Drug(s), 231, 311, 333, 317, 373 Clinical trials, 1049
Epoxide hydrolase, 277
Enzymes, 427 Clonogenic fraction, 57
Eppendorf oxygen electrodes, 439
Metabolism, 339, 357 Cobalt(III) complex, 323
Erythropoietin (r-HuEPO), 1079
Therapy, 427 Colon cancer, 277
Esophageal cancer, 525
Bleomycin, 705 Combined modality(ies), 481, 1027
Estramustine, 555
Blood Therapy, 153, 735
Estrogen receptor, 813
Flow, 481, 505 Complications, 529, 953
Etanidazole, 87, 289, 407, 535, 541, 545, 571,
Pressure, 455 Computed tomography, 863
611, 617
Bone marrow, 81 Concomitant chemoradiotherapy, 153
Etoposide, 39, 621
Transplant, 1167 Conformal radiation therapy, 755
Eulexin, 755
Transplantation, 847 Conservative treatment, 17
Experimental tumors, 463
Bone metastases, 1011 Craniospinal irradiation, 187
External beam therapy, 1133
Brachytherapy, 17, 617, 673, 681, 855, 863, Cryospectrophotometry, 459
873, 893, 1049 Cultured, 511
Brain, 571 Cumulative incidence, 1183 F
Brain, 1065 Cyclophosphamide, 39, 387, 545, 847
Neoplasm, 719, 1089 Cyclosporine, 847 '9F NMR, 95
Tumors, 617 Cytochrome C, 635 Fast neutron, 239
Breast Cytochrome P-450, 277 FIGO classification, 941
Cancer, 163 5-fluorouracil, 519
Positioning device, 879 5-iodo-2’-deoxiuridine, 105
Conserving therapy, 163 D Flavone acetic acid, 373
Breast carcinoma, 879 Fluorinated 2-nitroimidazole derivative, 579
Cells, 813 Determinants of radiocurability, 57 Fluorine radioisotope, 841
Buthionine sulfoximine, 403, 407, 3983 Differential action, 635 Fluoroscopy, 863
BW 589C, 285 Diffusible cytotoxin(s), 317, 323 Foot, 735
Diltiazem, 511 4-OOH-CP, 301
Dimethylxanthenone acetic acid, 373 Fractionated
C Dipole antennas, 1065 Irradiation, 583, 591
DNA Radiotherapy, 141, 1147
Calcium, 511 Bases, 307 Free radicals, 421
Canine, 1015 Binding, 311 FSa-II tumor, 141
XIX
G Immunofluorescence staining, 239 MDRI, 81
Immunohistochemistry, 277 Mechlorethamine, 317
Gamma-glutamylcysteine synthetase, 407 Immunomodulators, 627 Melanoma, 403
Gastrointestinal, 961 In phantom measurements, 1175 Melphalan, 463, 541
Gd-DTPA, 473 In vitro effect, 631 Metallothionein, 397
Gene expression, 813 In vivo diode dosimetry, 1175 Mice, 627
General and radiobiological factors, 673 Inflated cuff procedure, 455 Micronucleus assay, 239, 587
Genitourinary, 961 Inhomogeneity, 1157 Microwave(s), 1049, 1065
Germinoma, 1089 Interleukin 1, 805 Minor groove binding DNA ligands, 549
Glioblastoma, 407, 835 Internal mammary nodes, 903 Misonidazole, 87
Multiforme, 719 Interstitial Misoprostol, 273
Glioma, 427 Brachytherapy, 719 Misrepair, 1035
Glucose metabolism, 571 Hyperthermia, 1049 Mitomycin C, 363
Glutathione, 383, 393, 403, 407, 771 Intestine, 81, 781 Morphology, 771
Graft failure, 847 Intimal hyperplasia, 183 Mouse bone marrow cells, 631
Graft-versus-host disease, 847 Intracavitary gynecologic brachytherapy, 969 MRI, 95, 1095
Gynecologic, 961 Intraoperative radiotherapy, 781, 1015 mRNA, 397
Intratumoral chemotherapy, 1027 Multiple
Intrinsic radiosensitivity, 57 Daily fractions, 961
H Iodinated DNA ligands, 549 Head and neck, 681
Iodine-125, 719 Myeloma, 541
Halogenated pyrimidines, 105 Ionizing radiation, 249, 813 Multivariate analysis, 673
Hand, 735 Murine, 459
Hazard rates, 1183 Tumors, 439
HDR-brachytherapy, 183 K Muscle
Head and neck Blood perfusion, 473
Cancer(s), 45, 149, 153, 661, 687 Kaplan-Meier, 1183 Cramping, 379
Tumors, 1049 Karnofsky performance status, 835 Myelopathy, 763
Helical antennas, 1065 K curve, 323
Helium ions, 647 Ketoconazole, 777
Hematoxicity, 115 KHT sarcoma, 459, 473 N
Hep3B cells, 397 KIN-804, 595, 601
Hepatom, 277 KU-2285, 571, 579, 583, 587, 591, 595 NADH cytochrome b5, 427
Heterogeneity, 1157 NADPH cytochrome P-450 reductase, 427
High-LET, 115 Nasolacrimal
Histological types, 975 L Duct, 1095
Histopathology, 73 Sac cancer, 177
Hodgkin’s disease, 25 Lacrimal Nasopharyngeal carcinoma, 699
Hoechst 33258 DNA strand breaks, 549 Cancer, 177 Neoadjuvant hormonal therapy, 755
HT-29, 363 Collecting system, 1095 Neoplasm(s), 841, 855, 1095, 1119
Human(s), 455 Sac, 1095 Neoplastic cells, 511
Umbilical cord blood, 821 Laryngeal carcinoma, 657 Nervous system, 771
Xenografts, 57 Larynx, 841 Neurophysiology, 771
Human brain tumor(s), 427 Late Neurosurgery, 711
Cells, 1041 Complications, 1183 Neurotoxicity, 535, 571
Human tumor cell(s), 369 Effects, 73, 781 Neutron brachytherapy, 529
Lines, 1035 Leukemia, 1167 Nicotinamide, 455
Hydralazine, 473, 505 Leuprolide, 755 Nimorazole, 87
Hydrogen peroxide, 357 Limb preservation, 735 Nine bioreductive agents, 329 d
Hydroxamic acid, 601 Lipoxygenase, 777 Nitric oxide synthase, 443
Hyperfractionation, 45 Liver, 277 Nitro-L-arginine, 443
Hyperthermia, 125, 141, 511, 525, 821, 827, L929 cells, 467 Nitrogen mustard, 323
1065 Local Nitroimidazole, 601
Techniques, 1049 Control, 153, 1183 Nitroquinoline, 311
Hypoxia, 87, 231, 259, 373, 427, 449, 481, 493 Neoplasm recurrence, 841 Nitroreductases, 351
Effect on cytotoxicity, 363 Tumor control, 529 Nitrosochloramphenicol, 307
Of normal tissue, 487 Locally advanced, 873 Nitroxides, 421
Of tumor, 487 Long-circulating liposomes, 827 Nonelectronic equilibrium, 1139
Hypoxic Lonidamine, 45, 999 Nonsmall cell, 1105
Cytotoxic agents, 379 Low doses, 87 Lung cancer, 33, 999
Fraction (HF), 583 Low-dose rate Normal tissue, 487
Markers, 351 Brachytherapy, 953 Effects, 781
Selectivity, 311 Intracavitary brachytherapy, 975 Tolerance, 1015
Sensitization, 295 Lower gingiva, 705 Nuclear antigen, 661
Hypoxic cell Lung cancer, 635, 1085, 1105 Nude mice, 525
Fraction, 57 Lymphoid, 1095, 1095
Radiosensitizer(s), 571, 579, 587, 591, 595, Lysosomal uptake, 311
601 O
Sensitizer, 541, 545, 583
M OK-432, 631
Oncogenic transformation, 267, 273
I Magnetic resonance imaging (MRI), 473 l-electron reduction, 333
Malignant glioma, 719 Operable lung cancer, 33
IL-1 normal tissues: endogenous cytokines, 805 Mammary adenocarcinoma, 141 Oral
Immobilization device, 879 Marrow transplantation, 39 Cancer, 383
Immunocompetence, 821 MDAH-MCa-4 tumor, 373 Tongue carcinoma, 673
XX
Oropharynx, 681 R Smoking, 449
Outcome, 1005 SN 23862, 373
Ovarian Radiation, 267, 393, 565, 1095 SN 24771, 323
Cancer, 545 Enhancement, 999 Soft tissue sarcoma, 1005
Neoplasms, 169 Injuries, 841 Spermine analog, 1041
Overall treatment time, 983 Mucositis, 383 Spheroids, 317
Oxidative stress, 289 Myelopathy, 67, 73 Spinal cord, 67, 73
Oxygenation, 421 Resistance, 1035 Spontaneous tumors, 443
Oxyhemoglobin modifiers, 285 Response, 255, 449 Squamous cell
Sensitizer(s), 105, 379, 535, 555, 611, 617 Cancer, 243
Sensitizing agents, 345 Carcinoma, 705
Sequelae, 777 SR-2508, 289, 587
Radiation damage, 73 SR-4077, 249
P
Repair, 893 SR 4233, 357, 363, 373, 379, 493
Radiation therapy (RT), 9, 719, 735, 869, 903, Stents, 183
Palliation, 961 1079 Supra-additive, 267
Palliative irradiation, 1011 Treatment course, 657 Synchronized cells, 565
Patient Radical
Dose quality assyrance, 1175 Radiotherapy, 33
Movement, 1147 Vulvectomy, 989
Positioning, 869, 1147 Radiobiological hypoxia, 439 T
PD 144872, 301 Radiography, 1119
PDT, 463 Radiolysis, 333 Targeted a-endoradiotherapy, 115
Pelvic tumors, 1049 Radiopotentiation, 1041 Taxol, 267, 565
Pentose cycle, 357 Radioprotection, 273, 621, 627, 747 Temperal optimization, 893
Pentoxifyline, 433 Radiosensitization, 243, 481, 549 Tert-butyl hydroperoxide, 249
Penumbra modifier, 187 Radiosensitizers, 87, 519 Therapeutic radiology, 1119
Perfluorocarbon, 95 Radiosensitizing Thermochemotherapy, 827
Perioperative morbidity, 969 Activity, 579 Thermoradiosensitization, 133
Peripheral Effect, 595 Thermoradiotherapy, 125, 141, 505
Neuropathy, 535 Radiotherapy, 17, 25, 45, 169, 699, 705, 835, Thiol(s), 387
Neurotoxicity, 591 Depletion, 345
855, 873, 941, 983, 1005, 1049, 1089
p50, 449 Dosage, 169 3-aminobenzamide, 577
P450 reductase, 351 RB90740, 333 Three-dimensional (3-D) treatment planning,
PH effect on cytotoxicity, 363 RB 6145, 301 903, 1105, 1125
Pharmacokinetic(s), 339, 463, 535, 591, 595 Recruitment, 805 Three-year survival, 529
Parameters, 607 Rectal adenocarcinoma, 115 Thymidine labelling index, 805
Photodynamic therapy (PDT), 231, 329 Thymidylate synthase, 519
Recurrence, 719
Photogrammetry, 1147 Patterns, 989 Time-dose relationship, 153
Pineoblastoma, 729 Reductase, 277 Tirapazamine, 369, 379, 493
Pituitary shield, 699 Reduction of tirapazamine, 427 Tirazamine (WIN 59075, SR 4233), 427
Plasma GSH, 383 Regrowth delay, 463 TNF cytotoxicity, 467
Plasmid, 1035 Rehypoxiation, 493 Tolerance, 529
PLDR, 255 Reirradiation, 687 Total
3!P magnetic resonance spectroscopy (MRS), Reoxygenation, 141, 255, 493, 583 Body irradiation, 39, 1167
231, 285, 443 Repair, 133 Lymphoid irradiation, 847
Toxicity, 771
pO,, 95 Repopulation, 805
pO, distribution, 427 Reproducibility, 1175 Toxicology, 771
p105, 661 Response rates, 1011 TPA, 259
Positron emission tomography, 841 Restriction endonucleases, 1035 Transcription, 397
Postoperative radiation therapy, 989 Retinoblastoma, 393, 729 Transient hypoxia, 487
Potentially lethal damage repair, 239, 577 Retreatment, 1011 Transplantable tumors, 443
Predictive assay, 661 Retroperitoneal, 1005 Treatment planning, 1119, 1133
Preincubation effect, 345 Retroperitoneum, 781 Trilateral retinoblastoma, 729
Prognostic RIF-1 tumor, 329, 827 Tumor(s), 487, 571
Factors, 9, 711 RK-28, 571 Hypoxia, 285
Parameters, 1049 RP-170, 571 Microenvironment, 467
Proliferation, 661 Necrosis factor, 777
Prolonged treatment and local control, 657 pH, 125
Prostaglandins, 273 S Response, 125
Prostate, 863, 1119 Size, 9, 505
Apex, 1133 Salivary glands, 747 Tumor blood
Cancer, 611, 755, 1133 SAR, 1065 Flow, 433
Carcinoma, 555 Sarcoma, 735 Perfusion, 449, 473
Tumor, 95 SCCVII Tumor oxygenation, 459, 467
Protein kinase C, 259 Carcinoma, 459 Status, 439
Pyrazine mono-N-oxides, 339 Tumoral, general and radiobiological factoars,
Tumor, 81, 449
673
Scintillation detector, 1157
2-nitorimidazole(s), 345, 351, 535, 611, 617
Second
Derivative, 579
Cancers, 25
Head and neck carcinoma, 681
Q
Seminoma, 3
Sensitizing effect, 607 U
Quality assurance, 869 Signal transduction, 259
Quality of life, 835 Single brain metastasis, 71 | UDP-glucurony! transferase, 277
Quiescent cell, 239 Skull base tumors, 647 Ureter, 781
XXI
Urethra, 1119 Verapamil, 511 X
V79-WNRE, 363 Verification films, 869
Vitamin E succinate, 289 X ray, 577
Volume effects, 67, 763 Xenobiotic-metabolising enzymes, 277
Vv Vulvar carcinoma, 989 Xenografts, 481
Vaginal cancer, 983
Vascular grafts, 1015 Ww
Vasoactive, 373 Y
Velotonsillar carcinoma, 681 Whole-body irradiation, 621
Vena cava, 781 WR-2721, 747 Young and mature pigs, 763